Study Design:
Prospective, multi-center, single-arm, open-label, Phase 3 clinical study to 3 years with extension up to 5 years
Number of Subjects:
Approximately 1,605 subjects will be enrolled into the study
Study Population:
Post-menarcheal, pre-menopausal women up to age 45 years, who are at risk